Related Experiment Video

Updated: Jun 16, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

The 2024 ESC guidelines on atrial fibrillation: essential updates for everyday clinical practice

Giuseppe Boriani1, Davide Antonio Mei2,3, Marco Vitolo2

  • 1Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico Di Modena, Pozzo 71, 41121, Modena, Italy. giuseppe.boriani@unimore.it.

Internal and Emergency Medicine
|June 13, 2025
PubMed

Insights

The 2024 European Society of Cardiology guidelines offer crucial updates for managing atrial fibrillation (AF), including new risk scores and expanded treatment options. These changes aim to improve patient outcomes and streamline clinical practice for this common heart rhythm disorder.

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines
  • Cardiac Arrhythmias

Background:

  • Atrial fibrillation (AF) is the most common cardiac arrhythmia, causing significant morbidity, mortality, and healthcare costs.
  • Effective management of AF is essential due to its complexity and widespread impact.
  • Contemporary medicine requires updated strategies for optimal AF patient care.

Purpose of the Study:

  • To present key updates from the 2024 European Society of Cardiology (ESC) guidelines for atrial fibrillation (AF) management.
  • To highlight practical implications of these new guidelines for daily clinical practice.
  • To compare the 2024 ESC guidelines with previous ESC and American College of Cardiology/American Heart Association (ACC/AHA) guidelines.

Main Methods:

  • Review and synthesis of the 2024 ESC guidelines for AF management.
  • Identification of seven key areas of updated recommendations.
  • Comparative analysis of the 2024 ESC guidelines against prior ESC (2021) and ACC/AHA (2023) guidelines.

Main Results:

  • Introduction of the CHA₂DS₂-VA score for thromboembolic risk stratification.
  • Revised bleeding risk assessment strategies.
  • Expanded indications for catheter ablation and left atrial appendage closure.
  • Emphasis on the AF-CARE pathway and updated management of atrial high-rate episodes.
  • Consideration of artificial intelligence in predictive analytics for AF.

Conclusions:

  • The 2024 ESC guidelines provide essential updates for clinicians managing atrial fibrillation.
  • Adoption of these evidence-based recommendations can optimize patient care and outcomes.
  • Understanding regional differences and advancements is crucial for comprehensive AF management.

Keywords:
AblationArrhythmiaAtrial fibrillationGuidelinesStroke

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Related Concept Videos

Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
922
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
799
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
638